These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15027508)

  • 1. Sample sizes based on exact unconditional tests for phase II clinical trials with historical controls.
    Chang MN; Shuster JJ; Kepner JL
    J Biopharm Stat; 2004 Feb; 14(1):189-200. PubMed ID: 15027508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On group sequential designs comparing two binomial proportions.
    Kepner JL
    J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conservative sample size estimation in nonparametrics.
    De Martini D
    J Biopharm Stat; 2011 Jan; 21(1):24-41. PubMed ID: 21191852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval estimation of binomial proportion in clinical trials with a two-stage design.
    Tsai WY; Chi Y; Chen CM
    Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Samples of exact k-stage group sequential designs for Phase II and Pilot studies.
    Kepner JL; Chang MN
    Control Clin Trials; 2004 Jun; 25(3):326-33. PubMed ID: 15157732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review.
    Sahai H; Khurshid A
    Stat Med; 1996 Jan; 15(1):1-21. PubMed ID: 8614740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On Simon's two-stage design for single-arm phase IIA cancer clinical trials under beta-binomial distribution.
    Liu J; Lin Y; Shih WJ
    Stat Med; 2010 May; 29(10):1084-95. PubMed ID: 20077506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.